The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know.

[1]  Kenneth Offit,et al.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Julie O. Culver,et al.  Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. , 2015, Genetic testing and molecular biomarkers.

[3]  T. Trojanowski,et al.  Cowden syndrome and the associated Lhermitte-Duclos disease--Case presentation. , 2015, Neurologia i neurochirurgia polska.

[4]  R. Gibb,et al.  Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer , 2015, Cancer.

[5]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[6]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Mads Thomassen,et al.  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. , 2015, JAMA.

[8]  M. Goldacre,et al.  Age-specific risk of breast cancer in women with neurofibromatosis type 1 , 2015, British Journal of Cancer.

[9]  S. Narod,et al.  The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[10]  D. Alberts,et al.  Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. King,et al.  Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. , 2014, JAMA.

[12]  M. King,et al.  Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 , 2014, Proceedings of the National Academy of Sciences.

[13]  O. Olopade,et al.  Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers , 2014, Breast Cancer Research and Treatment.

[14]  J. Barnholtz-Sloan,et al.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Karlan,et al.  Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[17]  Julie O. Culver,et al.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress , 2013, Clinical genetics.

[18]  O. Olopade,et al.  The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation , 2013, Breast Cancer Research and Treatment.

[19]  Guofeng Zhang,et al.  Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk , 2013, Tumor Biology.

[20]  Diana Eccles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[21]  K. Offit,et al.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Chung,et al.  Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk , 2013, PLoS genetics.

[23]  V. Brouste,et al.  High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome , 2013, Journal of Medical Genetics.

[24]  E. John,et al.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Cross,et al.  CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  X. Ye,et al.  Increased risk of breast cancer in women with NF1 , 2012, American journal of medical genetics. Part A.

[27]  Soo-Hwang Teo,et al.  Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations , 2012, European Journal of Human Genetics.

[28]  T. Dörk,et al.  Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga‐Ural region , 2012, Clinical genetics.

[29]  J. Manson,et al.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. , 2012, The Lancet. Oncology.

[30]  E. Rosenthal,et al.  Clinical significance of large rearrangements in BRCA1 and BRCA2 , 2012, Cancer.

[31]  S. Gruber,et al.  Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort , 2012, Breast Cancer Research and Treatment.

[32]  S. Narod,et al.  BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. , 2012, Gynecologic oncology.

[33]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[34]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[35]  X. Geng,et al.  Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. , 2011, European journal of cancer.

[36]  Julie O. Culver,et al.  Genetics, genomics, and cancer risk assessment , 2011, CA: a cancer journal for clinicians.

[37]  Julie O. Culver,et al.  Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce , 2011, Genetics in Medicine.

[38]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[39]  Y. Bignon,et al.  Germline mutations of the E‐cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer , 2011, Cancer.

[40]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[41]  M. Yaffe,et al.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Rosen,et al.  The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. , 2011, Gynecologic oncology.

[43]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[44]  C. Greenwood,et al.  On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations , 2011, European Journal of Human Genetics.

[45]  W. Foulkes,et al.  Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. , 2010, Journal of the National Cancer Institute.

[46]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[47]  J. Lubiński,et al.  The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania , 2010, Clinical genetics.

[48]  M. Daly,et al.  Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer , 2010, PLoS genetics.

[49]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[50]  V. Pankratz,et al.  Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2010, Human molecular genetics.

[51]  S. Narod.  Testing for CHEK2 in the cancer genetics clinic: ready for prime time? , 2010, Clinical genetics.

[52]  C. Caldas,et al.  Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research , 2010, Journal of Medical Genetics.

[53]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[54]  J. Kładny,et al.  CHEK2 mutations and HNPCC‐related colorectal cancer , 2010, International journal of cancer.

[55]  D. Evans,et al.  Assessing women at high risk of breast cancer: a review of risk assessment models. , 2010, Journal of the National Cancer Institute.

[56]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[57]  F. Couch,et al.  Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers , 2010, Breast Cancer Research and Treatment.

[58]  M. Dąbrowska,et al.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.

[59]  S. Narod,et al.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Robson,et al.  CHEK2, breast cancer, and the understanding of clinical utility , 2009, Clinical genetics.

[61]  Barbara L. Smith,et al.  Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Edge.  Nipple-sparing mastectomy: how often is the nipple involved? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Nandita Mitra,et al.  Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. , 2009, Cancer research.

[64]  D. Malkin,et al.  High frequency of de novo mutations in Li–Fraumeni syndrome , 2009, Journal of Medical Genetics.

[65]  Christi J. van Asperen,et al.  Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? , 2009, Breast Cancer Research and Treatment.

[66]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[67]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[68]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Robin M. Cisco,et al.  Hereditary diffuse gastric cancer , 2008, Cancer.

[70]  T. Rebbeck,et al.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. , 2008, Cancer research.

[71]  O. Gemer,et al.  Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC). , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[72]  Annika Lindblom,et al.  Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Hopper,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[74]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[75]  P. Møller,et al.  Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Lubiński,et al.  Early radiation exposures and BRCA1-associated breast cancer in young women from Poland , 2008, Breast Cancer Research and Treatment.

[78]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[79]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[80]  F. Couch,et al.  Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. , 2007, Clinical breast cancer.

[81]  Anthony Howell,et al.  Breast cancer risk-assessment models , 2007, Breast Cancer Research.

[82]  Ross S Berkowitz,et al.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  G. Tomlinson,et al.  Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families , 2007, Cancer Epidemiology Biomarkers & Prevention.

[84]  Sarah M. Greene,et al.  What Women Wish They Knew Before Prophylactic Mastectomy , 2007, Cancer nursing.

[85]  Julie O. Culver,et al.  Limited family structure and BRCA gene mutation status in single cases of breast cancer. , 2007, JAMA.

[86]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[88]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[89]  C. Mathew,et al.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.

[90]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[91]  R. Scott,et al.  The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers , 2007, Cancer Epidemiology Biomarkers & Prevention.

[92]  D. Evans,et al.  Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening , 2006, Journal of Medical Genetics.

[93]  A. Whittemore,et al.  Population‐based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry , 2006, Human mutation.

[94]  A. M. Munhoz,et al.  Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. , 2006, Plastic and reconstructive surgery.

[95]  J. Chang-Claude,et al.  Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[97]  O. Olopade,et al.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  S. Gruber,et al.  Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome , 2006, Clinical Cancer Research.

[99]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[100]  P. Møller,et al.  Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. , 2006, The Lancet. Oncology.

[101]  M. Freeman,et al.  Applicability of the Nipple-Areola Complex-Sparing Mastectomy: A Prediction Model Using Mammography to Estimate Risk of Nipple-Areola Complex Involvement in Breast Cancer Patients , 2006, Annals of plastic surgery.

[102]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[103]  J. Eyfjörd,et al.  Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. , 2006, Journal of the National Cancer Institute.

[104]  F. Couch,et al.  Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers , 2005, International journal of cancer.

[105]  O. Olopade,et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  B. Ward,et al.  Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families , 2005, Genes, chromosomes & cancer.

[107]  A. Børresen-Dale,et al.  Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia , 2005, British Journal of Cancer.

[108]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[109]  O. Olopade,et al.  A Comparison of Bilateral Breast Cancers in BRCA Carriers , 2005, Cancer Epidemiology Biomarkers & Prevention.

[110]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[111]  S. Mazoyer.  Genomic rearrangements in the BRCA1 and BRCA2 genes , 2005, Human mutation.

[112]  B. Paz,et al.  Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  O. Olopade,et al.  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.

[114]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[115]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[116]  Päivi Heikkilä,et al.  CHEK2 variant I157T may be associated with increased breast cancer risk , 2004, International journal of cancer.

[117]  J. Lowery,et al.  Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[119]  D. Horsman,et al.  Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of the National Cancer Institute.

[120]  A. Jakubowska,et al.  A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.

[121]  J. Weitzel,et al.  Effects of a cancer genetics education programme on clinician knowledge and practice , 2004, Journal of Medical Genetics.

[122]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[124]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[125]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[126]  J. Weitzel,et al.  Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.

[127]  E. Winer,et al.  Attitudes, knowledge, risk perceptions and decision‐making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses , 2003, Psycho-oncology.

[128]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[129]  Carol L. Brown,et al.  Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. , 2003, Gynecologic oncology.

[130]  Shih-Jen Hwang,et al.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. , 2003, American journal of human genetics.

[131]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[132]  Rochelle L. Garcia,et al.  Pathologic findings in prophylactic oophorectomy specimens in high-risk women. , 2002, Gynecologic oncology.

[133]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[134]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[136]  A. Neugut,et al.  Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  P. Glazer,et al.  Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status , 2002, The Lancet.

[138]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  B. Friedenson.  Ovarian cancer, oral contraceptives, and BRCA mutations. , 2001, The New England journal of medicine.

[140]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[141]  S. Hayasaka,et al.  Cancer‐specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning , 2001, Psycho-oncology.

[142]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[144]  C. la Vecchia,et al.  Reproductive and hormonal factors and ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[145]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[146]  A. Fyles,et al.  Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? , 2000, Gynecologic oncology.

[147]  A. Howell,et al.  Clinical follow‐up after bilateral risk reducing (‘prophylactic’) mastectomy: mental health and body image outcomes , 2000, Psycho-oncology.

[148]  T. Sellers,et al.  Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. , 2000, JAMA.

[149]  P. Chappuis,et al.  Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. , 2000, Seminars in surgical oncology.

[150]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[151]  A. House,et al.  Stressful life events and difficulties and onset of breast cancer: case-control study , 1999, BMJ.

[152]  G. Giles,et al.  Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[153]  A. Aurias,et al.  Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families , 1999, British Journal of Cancer.

[154]  D. Evans,et al.  Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. , 1999, Human molecular genetics.

[155]  D. Stoppa-Lyonnet,et al.  Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. , 1999, Cancer research.

[156]  A. Mes-Masson,et al.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. , 1998, American journal of human genetics.

[157]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[158]  D K Gaffney,et al.  Pathobiologic characteristics of hereditary breast cancer. , 1998, Human pathology.

[159]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[160]  D. Fishman,et al.  No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. , 1998, Cancer research.

[161]  M. King,et al.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. , 1998, American journal of human genetics.

[162]  B. Modan,et al.  The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. , 1998, Human molecular genetics.

[163]  J. Fraumeni,et al.  Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.

[164]  A. Neugut,et al.  Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  J. P. Dunn.  Colorectal cancer screening. , 1997, The New Zealand medical journal.

[166]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[167]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[168]  D. Berry,et al.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[169]  E. Mariman,et al.  Localization of the gene for Cowden disease to chromosome 10q22–23 , 1996, Nature Genetics.

[170]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[171]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[172]  J. D. Thompson,et al.  BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.

[173]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[174]  L. Cannon-Albright,et al.  Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.

[175]  J. Rommens,et al.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families , 1994, Nature Genetics.

[176]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[177]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[178]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[179]  G. Lenoir,et al.  DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. , 1993, Archives of internal medicine.

[180]  S. Friend,et al.  Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. , 1992, Journal of the National Cancer Institute.

[181]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[182]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[183]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[184]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[185]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[186]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[187]  F. Arwert,et al.  The Cowden syndrome: a clinical and genetic study in 21 patients , 1986, Clinical genetics.

[188]  M. Wolf,et al.  Gowden's disease. A cutaneous marker of breast cancer , 1978 .

[189]  W. Foulkes,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[190]  B. Carter.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .

[191]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[192]  S. Miller,et al.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2012 .

[193]  L. Pierce,et al.  Radiotherapy in the treatment of hereditary breast cancer. , 2011, Seminars in radiation oncology.

[194]  J. Thigpen.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2011 .

[195]  M. Greene,et al.  Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? , 2011, American journal of obstetrics and gynecology.

[196]  A. Børresen-Dale,et al.  Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. , 2010, Journal of the National Cancer Institute.

[197]  D. Huntsman,et al.  Hereditary diffuse gastric cancer. , 2010, Cancer treatment and research.

[198]  K. Offit,et al.  American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  S. Plon.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2010 .

[200]  S. Narod,et al.  A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas , 2010, Breast Cancer Research and Treatment.

[201]  J. Stockman.  F18-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome , 2009 .

[202]  Sarah M. Greene,et al.  Positive, Negative, and Disparate—Women’s Differing Long‐Term Psychosocial Experiences of Bilateral or Contralateral Prophylactic Mastectomy , 2008, The breast journal.

[203]  D. Fishman,et al.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. , 2007, The Lancet. Oncology.

[204]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[205]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[206]  Julie O. Culver,et al.  Assessing breast cancer risk and BRCA1/2 carrier probability. , 2006, Breast disease.

[207]  B. Karlan,et al.  Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. , 2006, Gynecologic oncology.

[208]  J. Garber,et al.  Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. , 2006, Gastroenterology.

[209]  C. Amsterdam.  CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer , 2006 .

[210]  J. Weitzel,et al.  Outcomes from intensive training in genetic cancer risk counseling for clinicians , 2005, Genetics in Medicine.

[211]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  S. Narod,et al.  Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer , 2004, Familial Cancer.

[213]  D. Horsman,et al.  Cancer variation associated with the position of the mutation in the BRCA2 gene , 2004, Familial Cancer.

[214]  L. J. Schelven,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group , 2004 .

[215]  L. J. Schelven.  Impact of BRCA1 / BRCA2 counseling and testing on newly diagnosed breast cancer patients , 2004 .

[216]  Sandra L. Wong.  Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure , 2004 .

[217]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[218]  Arlos,et al.  EARLY GASTRIC CANCER IN YOUNG, ASYMPTOMATIC CARRIERS OF GERM-LINE E-CADHERIN MUTATIONS , 2001 .

[219]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[220]  S. Seal,et al.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene , 1997, Nature Genetics.

[221]  W. Morain,et al.  Cowden's disease: a further indication for prophylactic mastectomy. , 1986, Surgery.

[222]  M. Wolf,et al.  Cowden's disease: a cutaneous marker of breast cancer. , 1978, Cancer.